TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01538355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged Fasting
Description: Patients enhance their regular diet with an initial 7-day fasting episode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic low glycemic load treatment
Description: 6 months of ketogenic low glycemic load treatment from the study outset.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Patients stay on their regular diet.
Study: NCT00869453

Intervention type: OTHER
Intervention: glucose
Description: administration of a glucose meal

Intervention type: OTHER
Intervention: fat
Description: administration of a lipid meal
Study: NCT02765815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine, 266mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5 % with Epinephrine
Study: NCT00869453

Intervention type: OTHER
Intervention: protein
Description: administration of a protein meal
Study: NCT02765815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% with Epinephrine
Study: NCT02667041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQore rTMS Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQore rTMS Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroQore rTMS Device
Study: NCT02101996

Intervention type: OTHER
Intervention: high-fat diet
Description: Subjects consume a high-fat diet for three weeks before the in-hospital stay.

Intervention type: OTHER
Intervention: high-fat diet
Description: Subjects consume a high-fat diet for three weeks before the in-hospital stay.
Study: NCT02619591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: views of a hemithorax was obtained using the Zonare Ultrasound machine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: views of a hemithorax was obtained using the Zonare Ultrasound machine.
Study: NCT04249492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental (Isopure 1.2.3.)
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator (Micropure 1.2.3.)
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
Study: NCT00869453

Intervention type: OTHER
Intervention: control
Description: no meal
Study: NCT04046159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen
Description: Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast radiotherapy
Description: Ipsilateral breast tumor recurrence and side effect
Study: NCT04025255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Braini
Description: A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02233140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-corporeal pulsed-activated therapy or shockwave therapy
Study: NCT00553514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
Study: NCT02233140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra-corporeal pulsed-activated therapy or shockwave therapy
Study: NCT01254786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-dependent lung ventilation
Description: the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-dependent lung ventilation
Description: the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min
Study: NCT02300506

Intervention type: OTHER
Intervention: No intervention
Study: NCT04093206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EpiCor and Vitamin C
Description: One daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: One daily dose
Study: NCT04535258

Intervention type: DEVICE
Group type: OTHER
Intervention: Blend-A
Description: Treatment for alcohol use disorders will be offered also as an internet-based option.

Intervention type: DEVICE
Group type: OTHER
Intervention: Blend-A
Description: Treatment for alcohol use disorders will be offered also as an internet-based option.

Intervention type: DEVICE
Group type: OTHER
Intervention: Blend-A
Description: Treatment for alcohol use disorders will be offered also as an internet-based option.

Intervention type: DEVICE
Group type: OTHER
Intervention: Blend-A
Description: Treatment for alcohol use disorders will be offered also as an internet-based option.
Study: NCT01402375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone (first trial)
Description: Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine (first trial)
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone (for second trial)
Description: Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine (for second trial)
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone (third trial)
Description: Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone (third trial)
Description: Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
Study: NCT00636506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMS 700 IPP with MS Pump
Description: AMS 700 Series Inflatable Penile Prosthesis with MS Pump
Study: NCT04050891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: combined supraclavicular and interscalene block
Description: Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block.
Study: NCT03304769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
Study: NCT00284609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based non-pharmacological rehabilitation
Description: 6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual non-pharmacological rehabilitation
Description: Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month
Study: NCT02089178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous anesthesia
Description: total intravenous anesthesia group: propofol-remifentanil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia
Description: inhalation anesthesia group: sevoflurane-remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol-remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane-remifentanil
Study: NCT01670825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Description: Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
Study: NCT01644032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation between paramedics and an EMS physician
Study: NCT00442637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine + bevacizumab
Description: Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
Study: NCT01670825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anethestic injection
Study: NCT00442637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observation
Description: observation after induction treatment
Study: NCT00547066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: hA20 will be administered intravenously in two doses over two weeks
Study: NCT01670825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anethestic injection
Study: NCT04841681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Psychotherapy
Description: Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation.
Study: NCT03263169

Intervention type: BEHAVIORAL
Intervention: Community-based personalized care
Description: volunteer support, health technology, interprofessional care, social network linkage

Intervention type: BEHAVIORAL
Intervention: Community-based personalized care
Description: volunteer support, health technology, interprofessional care, social network linkage
Study: NCT03999333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (Oculus Go)
Description: Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
Study: NCT01841164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for montelukast
Description: Sugar pills manufactured to mimic Singulair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled leukotriene E4
Description: Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled leukotriene E4
Description: Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
Study: NCT03285061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deterra Drug Deactivation System
Description: A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
Study: NCT03687931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Drop
Study: NCT03253055

Intervention type: RADIATION
Intervention: pQCT
Description: A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.

Intervention type: OTHER
Intervention: Lifestyle Questionnaire
Description: Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.

Intervention type: OTHER
Intervention: Lifestyle Questionnaire
Description: Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.

Intervention type: OTHER
Intervention: Lifestyle Questionnaire
Description: Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
Study: NCT01511692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 1.8 mg/day injected subcutaneously for 4 weeks
Study: NCT03648190

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry analysis of platelets surface receptors
Description: BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs).

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry analysis of platelets surface receptors
Description: BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs).
Study: NCT00732849

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Reconvan, Dipeptiven, Omegaven
Description: Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Reconvan, Dipeptiven, Omegaven
Description: Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconvan, Dipeptiven, Omegaven
Description: Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconvan, Dipeptiven, Omegaven
Description: Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
Study: NCT03253055

Intervention type: OTHER
Intervention: Aerobic Fitness
Description: Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
Study: NCT00800527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 800 mg one a day up to 30 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac 75 mg one a day up to 30 day
Study: NCT03253055

Intervention type: OTHER
Intervention: Aerobic Fitness
Description: Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.

Intervention type: OTHER
Intervention: Aerobic Fitness
Description: Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.

Intervention type: OTHER
Intervention: Muscular Strength
Description: Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.

Intervention type: OTHER
Intervention: Muscular Strength
Description: Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
Study: NCT03176862

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance scan
Description: An MRI scan of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance scan
Description: An MRI scan of the heart
Study: NCT03253055

Intervention type: OTHER
Intervention: Muscular Strength
Description: Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.

Intervention type: BIOLOGICAL
Intervention: Blood draw and finger prick test
Description: 15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count

Intervention type: BIOLOGICAL
Intervention: Blood draw and finger prick test
Description: 15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count

Intervention type: BIOLOGICAL
Intervention: Blood draw and finger prick test
Description: 15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count

Intervention type: OTHER
Intervention: Muscular Power
Description: Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.

Intervention type: OTHER
Intervention: Muscular Power
Description: Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.

Intervention type: OTHER
Intervention: Muscular Power
Description: Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
Study: NCT03608865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab with Tremelimumab
Description: Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
Study: NCT03176862

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance scan
Description: An MRI scan of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test with stress echocardiogram
Description: An exercise bicycle test with echocardiogram done during the exercise.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test with stress echocardiogram
Description: An exercise bicycle test with echocardiogram done during the exercise.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ECG holter monitor
Description: 3 stickers attached to a small monitor are worn for 24 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ECG holter monitor
Description: 3 stickers attached to a small monitor are worn for 24 hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG
Description: Can be done immediately by the bedside.

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG
Description: Can be done immediately by the bedside.

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG
Description: Can be done immediately by the bedside.